Trial Population & Randomization
Placeholder: broad CVD-plus-obesity cohort, diabetes not required for entry.
- 17,604: Patients randomized (placeholder cohort size)
- 41 / ~800: Countries / sites (placeholder global reach)
- ≥27: BMI entry criterion (placeholder threshold)
- No: Diabetes required (placeholder key criterion)
Who was enrolled
Placeholder: adults 45+, established CVD, overweight or obese.
Randomization design
Placeholder: 1:1 semaglutide 2.4mg vs placebo, double-blind.
Why non-diabetic matters
Placeholder: isolates CV benefit from glycemic control effects.
Placeholder: broadens relevance beyond diabetes-only prior trials.
Treatment Period & Weight Trajectory
Placeholder: semaglutide arm sheds weight steadily; placebo stays flat.
- -9.4%: Weight Δ semaglutide (wk65) (placeholder trial mean)
- -0.9%: Weight Δ placebo (wk65) (placeholder trial mean)
- 16 wks: Dose titration (placeholder schedule)
- 2.4 mg: Maintenance dose (placeholder weekly SC)
GLP-1 mechanism
Placeholder: appetite suppression via hypothalamic GLP-1 receptor agonism.
Divergence timeline
Placeholder: separation visible by month 2, plateaus later.
Placebo arm behavior
Placeholder: standard-of-care only, minimal weight change.
Blood Pressure, Lipids & Inflammation
Placeholder: cardiometabolic markers improve alongside weight loss.
- -38%: hs-CRP Δ semaglutide (placeholder relative change)
- -3.8 mmHg: Systolic BP Δ (placeholder mean drop)
- -8.2 cm: Waist circumference Δ (placeholder mean drop)
- Improved: Lipid panel (placeholder direction)
Inflammation marker
Placeholder: CRP falls faster and further on treatment.
Blood pressure trend
Placeholder: modest systolic reduction tracks weight loss.
Mechanistic link
Placeholder: risk factor shifts plausibly mediate CV benefit.
Placeholder: benefit appears partly independent of weight loss alone.
MACE Accumulation Over Follow-up
Placeholder: event curves separate gradually across ~40 months.
- 39.8 mo: Median follow-up (placeholder duration)
- MACE: Primary endpoint (CV death, MI, stroke)
- 6.5%: Events, semaglutide (placeholder cumulative)
- 8.0%: Events, placebo (placeholder cumulative)
Composite endpoint
Placeholder: CV death, nonfatal MI, nonfatal stroke combined.
Kaplan-Meier separation
Placeholder: curves diverge early and widen over time.
Consistency across subgroups
Placeholder: benefit broadly consistent regardless of baseline weight.
Statistically Significant Risk Reduction
Placeholder: semaglutide lowers MACE risk independent of diabetes status.
- 0.80: Hazard ratio (placeholder 95% CI 0.72–0.90)
- ~20%: Relative risk reduction (placeholder headline result)
- <0.001: P-value (placeholder significance)
- NEJM 2023: Publication (placeholder citation)
Headline result
Placeholder: ~20% relative MACE reduction versus placebo.
Diabetes-independent benefit
Placeholder: effect held regardless of glycemic status.
Placeholder: expands GLP-1 cardioprotection beyond diabetic populations.
Clinical implication
Placeholder: obesity itself becomes a treatable CV risk target.
Open questions
Placeholder: durability, mechanism weighting, and access remain under study.